.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,071,876

« Back to Dashboard

Details for Patent: 6,071,876

Title: Method of preventing NMDA receptor complex-mediated neuronal damage
Abstract:Disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric-oxide or related redox species, in a concentration effective to effect neuroprotection. Also disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric oxide (or a related redox species such as NO.sup.- or NO.sup.+ equivalent), or a physiologically concentration effective to cause such neuroprotection.
Inventor(s): Lipton; Stuart A. (Newton, MA), Stamler; Jonathan (Chapel Hill, NC)
Assignee: Children's Medical Center Corporation (Boston, MA)
Filing Date:Aug 21, 1998
Application Number:09/138,580
Claims:1. A method of decreasing NMDA receptor-mediated neuronal damage in a mammal comprising administering to a patient a composition comprising a component selected from the group consisting of: superoxide dismuta se (SOD); an SOD mimic; catalase; combinations of at least two ingredients, said first ingredient being SOD or said mimic and said second ingredient being catalase.

2. The method of claim wherein said patient is infected with a human immunodeficiency virus (HIV) and said method treats neurological manifestations of HIV infection.

3. The method of claim 1 wherein said patient suffers from amyotrophic lateral sclerosis (ALS) and said method treats neurological manifestations of ALS.

4. The method of claim 1 wherein said patient suffers from neuropathic pain mediated by NMDA receptor activity.

5. The method of any one of claims 1-4, wherein said component is formulated in polyethylene glycol or liposomes to enhance central nervous system absorption and efficacy.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc